Therapies in the Pipeline for Systemic Autoimmune Diseases - European Medical Journal

Therapies in the Pipeline for Systemic Autoimmune Diseases

Rheumatology
Download PDF
Authors:
*Juan Felipe Betancur,1 Jose Fernando Molina,2 Gabriel J. Tobón3
Disclosure:

The authors have declared no conflicts of interest.

Received:
10.03.16
Accepted:
10.05.16
Citation:
EMJ Rheumatol. ;3[1]:118-127. DOI/10.33590/emjrheumatol/10311528. https://doi.org/10.33590/emjrheumatol/10311528.
Keywords:
Systemic lupus erytematosus (SLE), Sjögren’s syndrome (SS), anti-phospholipid syndrome (APS), new therapies

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

The current goals in the development of novel therapeutics of systemic autoimmune diseases are to develop agents more effective than conventional therapies as well as to reduce the risk of organ damage. To achieve this goal, large multicentre randomised controlled trials are needed to confirm the efficacy and safety of novel agents. Whether these novel modalities are synergistic to conventional drugs, the optimal dosages, and duration of treatment, need to be explored.

As expected, the development of new molecules for the treatment of autoimmune diseases is constant, and there are different ongoing clinical trials. We review the different molecules in the pipeline, summarised in Tables 1, 2, and 3. We also show the successes, failures, and molecules that require more evidence.

Please view the full content in the PDF above. 

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>